Cellistic

Cellistic

Biotechnology Research

Delivering the iPSC platforms that ready the world for next-gen cell therapies

About us

Launched in April 2022, Cellistic specializes in process development and manufacture of cell therapies based on human induced pluripotent stem cell (iPSC) technology. The company’s focus and expertise in iPSC generation and differentiation protocol development makes it well-positioned to partner with innovative cell therapy developers to establish novel advanced therapies. With more than a decade of scientific and technical knowledge transfer from sister company Ncardia, Cellistic is uniquely experienced in designing and optimizing manufacturing procedures for iPSCs that deliver quality products at scale. For more information, visit www.cellistic.com.

Industry
Biotechnology Research
Company size
51-200 employees
Headquarters
Mont-Saint-Guibert
Type
Privately Held

Locations

Employees at Cellistic

Updates

Similar pages